The Economic Club of Colorado would like to welcome Alan Wilson as a new member. Alan Wilson joined the Cancer Treatment Centers of America® (CTCA) family of enterprises in 2008 and has been instrumental in shaping and refining how innovation and intellectual property work in partnership for the benefit of cancer patients and caregivers across the globe for the past ten years. With a disciplined business framework and commitment to excellence, Alan has been at the forefront of identifying business opportunities that align with global needs, leveraging technology and data insights to develop products and strategic initiatives to help patients worldwide.
In his current roles as the Principal of Brown Legacy Group and the CEO of Novintum Biotechnology GmbH and Novintum Medical Technology GmbH, Alan leads global strategy, enterprise structuring and the development of world-class management teams. Novintum Biotechnology, the management company behind Novintum Bioscience Ltd. (London), is at the forefront of a new wave in oncology drug development focused on therapeutics targeting the Tumor Metabolic Ecosystem, including cancer stem cells. Novintum Medical Technology, the management company of Physeon GmbH (Schaffhausen, Switzerland), has brought to market a first-in-class electrophysiological medical technology that improves venous access for patients around the globe.